Clinical trials
Allogeneic Hematopoietic Stem Cell Transplantation clinical trials
Below are recruiting allogeneic hematopoietic stem cell transplantation clinical trials, each written for real people, not researchers. We’re tracking 262 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07709195RecruitingPhase 2
Chlorophyllin to reduce mouth sores from radiation before transplant
This trial tests whether taking chlorophyllin can reduce mouth sores caused by total body radiation given before a stem cell transplant. The goal is to make the treatment easier to tolerate.
Navi Mumbai, MaharashtraAges 12–65 - NCT07693881Recruiting
Preventing EBV reactivation with rituximab after stem cell transplant in children
This trial tests whether adding a drug called rituximab to the standard transplant plan can help prevent Epstein-Barr virus (EBV) from reactivating in children receiving a half-matched stem cell transplant. It may help reduce a common viral complication after transplant.
GuangzhouAges Up to 18 years - NCT07688759Recruiting
Immune response measurement for first CMV after transplant
This trial is for adults who have had a stem cell transplant and now have their first CMV infection. It tests a way to measure your immune response to CMV, which may help doctors decide the best treatment for you.
Suzhou, JiangsuAges 18 years+ - NCT06589089RecruitingPhase 2
Stem cell boost after CAR-T for lymphoma
This trial tests giving patients their own stored stem cells after CAR-T therapy to help recover low blood counts. It is for people with B-cell non-Hodgkin lymphoma whose blood counts are still low after CAR-T and who have a stable response to treatment.
ShanghaiAges 18 years+ - NCT07685457Recruiting
Virus-specific T cells for stubborn viral infections after transplant
This trial tests whether specially trained immune cells (virus-specific T cells) can safely treat stubborn viral infections after a stem cell transplant. It focuses on children and young adults who have not responded to standard antiviral treatments.
SeoulAges 1–25 - NCT07670468RecruitingPhase 1/Phase 2
T-cell therapy for resistant viral infections after transplant or cancer treatment
This trial tests a special T-cell treatment (LB-DTK-MV) for people with virus infections (CMV, BKV, EBV) that did not get better with standard medicines. It is for patients who had a stem cell transplant or certain cancer therapies like CAR-T or bispecific antibodies.
SeoulAges 19 years+ - NCT07648992RecruitingPhase 4
ATG dosing strategy for unrelated donor stem cell transplant
This trial tests a personalized approach to using ATG (a medicine that reduces immune rejection) in patients receiving stem cell transplants from unrelated donors for blood cancers. The goal is to improve transplant success while reducing side effects by tailoring ATG doses to individual patients.
Beijing, Beijing MunicipalityAges 14–65 - NCT06702111Recruiting
Outcomes after donor stem cell transplant
This study looks at how well patients do after receiving a stem cell transplant from a donor (called an allogeneic transplant). It aims to better understand the long-term outcomes and help improve care for future patients.
Hong KongAges 18 years+ - NCT06708130Recruiting
Stem cell transplant tracking study
This study tracks patients who have had or are planning to have a stem cell transplant. It helps doctors learn more about long-term outcomes and improve care for future patients.
Shanghai, Shanghai MunicipalityAges Any age - NCT05745532RecruitingEarly Phase 1
Autologous stem cell treatment to improve beta thalassemia major
This early-phase trial tests a new way to restore working blood-making cells using your own stem cells for people with transfusion-dependent beta thalassemia major. The goal is to improve safety and blood results, and possibly reduce problems from the disease.
Shenzhen, GuangdongAges 8–16 - NCT07607197RecruitingPhase 1/Phase 2
Immune Reset to Help Highly Sensitized Kidney Transplant Patients
This study tests whether a special immune-resetting treatment can help patients who have developed too many antibodies against donor kidneys get access to a compatible kidney transplant. The treatment uses chemotherapy and stem cell transplantation to 'reset' your immune system so it stops rejecting potential donor kidneys.
Barcelona, CataloniaAges 18–60 - NCT06715046Recruiting
Blood DNA test after stem cell transplant
This study checks if looking at DNA in your blood can help doctors see how well your stem cell transplant is working and catch any problems early. It is for people with blood cancers getting a transplant from a donor.
Milan, MilanAges 18 years+ - NCT07579065Recruiting
Care Plan Support After Blood Cancer Stem Cell Transplant
This study tests whether a personalized care plan helps blood cancer patients and their caregivers manage life after stem cell transplant. Researchers want to see if this plan makes recovery smoother and improves quality of life.
Reggio EmiliaAges 18 years+ - NCT07583888RecruitingPhase 2/Phase 3
VABu Conditioning for Older Adults with Acute Myeloid Leukemia
This trial tests a chemotherapy regimen (VABu) combined with a stem-cell transplant for older adults (60+) with acute myeloid leukemia (a blood cancer) who previously responded well to Venetoclax-based treatment. The goal is to see if this approach improves outcomes after transplant.
Suzhou, JiangsuAges 60 years+ - NCT07582172RecruitingPhase 2
Stem Cell Transplant for Hard-to-Treat Blood Cancers in Older Adults
This trial tests a new combination of radiation and chemotherapy to prepare your body for a stem cell transplant from a matched donor. It's designed for older patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that hasn't responded well to standard treatments.
Duarte, CaliforniaAges 18 years+ - NCT07569653RecruitingPhase 4
CMV Prevention After Stem Cell Transplant Using Blood Tests
This trial tests whether doctors can safely stop a CMV prevention medication (letermovir) earlier by using blood tests to check your immune system's strength. CMV is a virus that can become dangerous after stem cell transplant, and this study aims to prevent it while minimizing unnecessary medicine.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07569055Recruiting
Fungal Infections After Stem Cell Transplants: Long-Term Study
This study follows patients who have received a stem cell transplant from a donor to track and understand fungal infections that can occur afterward. By studying this carefully, researchers hope to better prevent and treat these serious infections in future patients.
Beijing, Beijing MunicipalityAges Any age - NCT07572669RecruitingPhase 2
Moxibustion for Steroid-Resistant Graft-Versus-Host Disease
This trial tests whether moxibustion—a traditional Chinese medicine technique using heat from burning mugwort—can help treat acute graft-versus-host disease (a complication after bone marrow transplant) that hasn't responded to steroid drugs. If you've had a stem cell transplant and developed this condition that won't go away with standard treatment, this study may be for you.
Wuhan, HubeiAges 14–65 - NCT07565220RecruitingPhase 1
Thiotepa-based stem cell transplant for blood cancers
This trial tests a new chemotherapy preparation (using thiotepa) before a stem cell transplant from a matched donor to treat blood cancers like leukemia and myelodysplastic syndrome. The goal is to improve survival while reducing severe side effects.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07564453RecruitingPhase 2
Immunotherapy plus chemotherapy for newly diagnosed B-cell leukemia
This trial tests a combination of immunotherapy (using the immune system to fight cancer) and chemotherapy in adults aged 15–65 with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL), a blood cancer. The goal is to see if this combination helps patients achieve remission and survive longer.
Suzhou, JiangsuAges 15–65 - NCT07559695Recruiting
Menin inhibitor maintenance therapy after stem cell transplant
This study tracks how well a newer drug class (menin inhibitors) works to prevent acute leukemia from coming back after a stem cell transplant. You would be observed for safety and effectiveness if you're already taking one of these drugs.
Suzhou, JiangsuAges 15 years+ - NCT07548983RecruitingPhase 1
Maintenance therapy after stem cell transplant for AML
This trial tests whether taking two drugs, ruxolitinib and azacitidine, after a reduced-intensity stem cell transplant can help prevent acute myeloid leukemia (AML) from returning. It is for patients who are in remission and at high risk of relapse.
Portland, OregonAges 18 years+ - NCT05762211RecruitingPhase 2
Oral probiotic to prevent complications after stem-cell transplant
This Phase 2 study tests an oral “fecal microbiotherapy” treatment given before and around an allogeneic (donor) stem-cell transplant to help prevent transplant-related complications. It may help by improving gut and immune function during the high-risk transplant period.
AntwerpAges 50 years+ - NCT07535645RecruitingPhase 1/Phase 2
Baricitinib for Low Platelet Counts After Bone Marrow Transplant
This trial tests whether a medication called baricitinib can help patients whose platelet counts remain dangerously low after a bone marrow transplant, even after standard treatments. Platelets are blood cells that help stop bleeding, and this study aims to see if baricitinib can restore them.
Beijing, Beijing MunicipalityAges 18–70
Hear when a new Allogeneic Hematopoietic Stem Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for allogeneic hematopoietic stem cell transplantation?
- Yes. Clin2 currently lists 262 recruiting allogeneic hematopoietic stem cell transplantation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a allogeneic hematopoietic stem cell transplantation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a allogeneic hematopoietic stem cell transplantation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient
- Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
- Hematopoietic Stem Cell Transplantation
- Allogeneic Stem Cell Transplantation
- Haploidentical Hematopoietic Stem Cell Transplantation
- Autologous Hematopoietic Stem Cell Transplantation
- Hematopoietic Stem Cell Transplant
- Stem Cell Transplantation
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.